Compare BZ & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | KOD |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.2B |
| IPO Year | 2021 | 2018 |
| Metric | BZ | KOD |
|---|---|---|
| Price | $12.67 | $100.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 7 |
| Target Price | $20.75 | ★ $129.50 |
| AVG Volume (30 Days) | ★ 4.7M | 785.6K |
| Earning Date | 11-25-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | $11.83 | N/A |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.12 | $18.15 |
| 52 Week High | $22.49 | $112.31 |
| Indicator | BZ | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 26.94 | 56.26 |
| Support Level | N/A | $81.11 |
| Resistance Level | $14.77 | $103.67 |
| Average True Range (ATR) | 0.69 | 6.73 |
| MACD | -0.55 | -0.34 |
| Stochastic Oscillator | 8.67 | 50.65 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.